Blue Horseshoe Stocks: Options Recap, New Ideas

Options Recap

We ended our week with some fresh options ideas on Friday, which, like a good majority of our ideas, saw chances for multibag gains on the day.

ULTA Weekly $320-327.50 Calls*
$320 Calls – Range:
9.20-17.60 – Max Gain: 78%
$322.50 Calls – Range: 8.80-18.80 – Max Gain: 108%
$325 Calls – Range: 4.90-19.26 – Max Gain: 108%
$327.50 Calls – Range: 5.10-16.74 – Max Gain: 110%
_____

SPY Weekly $280.50-281.50 Calls*
$280.50 Calls – Range: .40-1.65 – Max Gain: 78%
$281 Calls – Range: .14-1.24 – Max Gain: 108%
$281.50 Calls – Range: .09-.79 – Max Gain: 108%

Fresh Ideas:
SPY 03/18 $281-282 Calls*

FIS 04/18 $110-115 Calls

*As always when we signal options expiring the same day of our report, we must insist that you NOT attempt any of these trades unless you are an advanced level trader with access to disposable funds!


Qudian, Inc. QD

We’re looking at a potential bottom-play in QD as we kick off the week also, which as you can see on the following snapshot, has a ripening chart at the moment. The company reported earnings this morning, which beat expectations, while revenues fell slightly short.

The stock could be setting up for another run at the $7.00 range or better, so we’re going to begin monitoring QD in upcoming sessions.


Extended Watchlist:
ABIO, ADOM, NAKD, SFET, NSPR,

Blue Horseshoe Stocks: SSLJ New Highs & More

SSLJ.com Ltd. SSLJ

We included a reminder on SSLJ in yesterday’s premarket report, the second time since our initial alert on the Tuesday before last wherein we expressed our interest in the stock as a bottom play.

The stock subsequently experienced a low of .64 and while it had already made significant headway as of yesterday morning, the session brought even more impressive gains our way.

We mentioned it could move to fill its gap on the chart and it did so. The stock traded in a daily range from 1.72 to a new high of 3.00. That works out to an intraday run of 74% and represented a total increase of 369% from our observed low in just two weeks!


Advanced Micro Devices AMD

We recently had great success with some AMD options plays, a stock that we often use for that purpose, but didn’t talk much about the real story, which is the stock’s incredible rise this spring and summer.

We talk about AMD quite often in fact, with one of those alerts coming several months ago on April 26th. Since then, the stock has essentially done very little other than bull its way to impressive new highs. Subsequent to that April alert, it was trading at lows of 10.61 and it never looked back. The stock reached new highs of 20.18, a 90% increase. It’s rare to see such a big stock make a double but AMD has certainly gotten close over the past few months of activity.


Extended Watchlist:
HYRE, CGNX, ABIO, SPWR, GST, I

Blue Horseshoe Stocks: FL Recap & More

Footlocker, Inc. FL – Recap

On Friday, we cited a big profit and sales beat on Foot Locker’s Q1 earnings report, noting that we have had good luck with the company’s earning chain in the past. Our designated targets were the FL 06/15 $52.50-55 Calls. Lightning struck for us once again as FL surged and our ideas took off.

The $52.50 Calls ran hard from a low of 1.30 and subsequently hit a high of 4.50. That works out to a daily rip of 246% Meanwhile, the $55 Calls went on a slightly more intense ride, trading in a range from .65-2.54 for total possible intraday gains of 291%


ArQule, Inc. ARQL
It was just this past Wednesday morning that we were mentioning our late April call on ARQL which allowed us to catch the stock when it was trading as low as 2.40. ARQL had, at the time of last week’s mention, breached into the four-dollar range, but after a fruitful finish to the week, we have to circle back to comment on its impressive new highs.

In its fifth consecutive trading day of posting higher lows and higher highs, the stock reached a new high of 5.29, pushing our one month observed increase on the stock to 120%



Tintri, Inc. TNTR

We also want to place TNTR on bottom watch as we kick off the short trading week, after noticing that the stock has been absolutely crushed in the past week. It had already been on a steady downward trajectory, but as you can see below, the selloff really kicked into high gear just last week.

We’ve also noticed a rapid rise in the short volume, accounting for more than 1.2M of the stocks total volume on Friday. With the stock already having been egregiously oversold, this type of scenario can often lead to a short squeeze, and we will want to be ready to ride TNTR on the way back up, if that occurs.


Extended Watchlist:
ABIO, SBOT, MYSZ, CVPR, LPL, KTOV, OLED, VPLM(News)

Blue Horseshoe Stocks: ABIO Recap & More

ARCA BioPharma, Inc. ABIO

Our top performer from yesterday’s report was most assuredly ABIO. We tagged this play after noticing that it had announced being granted orphan drug status by the FDA for “rNAPc2″ as a potential treatment of viral hemorrhagic fever post-exposure to the Ebola virus.

Fresh FDA-related plays can often provide a healthy move to take advantage of, and that’s just what we got from ABIO, The stock traded in a range from .82-1.03, an intraday increase of 25% on nearly ten times the 3-month average volume.

Our long-time readers might recall our coverage of this stock last year in December, which sort of got lost in the shuffle that was the hysteria created by the “Green Rush”. We tracked the stock from the low 1.40′s to over 2.20 over a period of a few weeks, so it will be interesting to see if history continues to repeat itself with ABIO, especially with the stock coming off of it 52-week low on Tuesday.


CYREN Ltd. CYRN

We also wanted to acknowledge the early morning move made by another of the stocks we mentioned in yesterday’s newsletter, CYRN. It bolted out of the gate, quickly running from 2.22 to 2.67, a 20% spike within the first 15 minutes of the session.

The stock got hammered into the close quite a bit, so we’ll be open to the possibility of seeing some bounce action, provided it can hold support at or above the 50DMA of 1.75.


Office Depot, Inc. ODP

ODP is in the midst of making a big move on the heels of large activist investor Starboard Value taking up a position which equates to 6% of ODP’s total shares. It also upped its stake in Staples to 10% fueling speculation that it could create pressure for the two office supply giants to merge. It will definitely be a story that we’ll be interested to follow moving forward.


Extended Watchlist:
GPT, RGDX, CYTX, DRD

Blue Horseshoe Stocks: LXRP News Update & FDA-Related Plays

Lexaria Corp. LXRP

Following our initial report on LXRP yesterday, the stock had a productive session as it traded in a range from .095 to a high of .108, an intraday gain of 14% on roughly 2.5X the monthly average volume. It closed at .102 holding more than half of the day’s gains, which is generally a good sign.

We promised to relay any further updates regarding the current status of LXRP, and sure enough the company published a fresh PR this morning containing another major development. It relates to the sale of Lexaria’s domestic oil assets, which we mentioned in yesterday’s report, becoming final with all funds received. It provides LXRP with a cash infusion of $1.4M which will facilitate a clearing of all debt currently on the books, as well as advance the company’s plans to release a CBD-infused tea (infusion method is patent pending) via a new online sales portal. With the rate at which LXRP has been executing its strategies, we expect to hear about the opening of that website any day now.

KELOWNA, BC / ACCESSWIRE / December 10, 2014 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce the sale of all its Belmont Lake oil assets for $1.4 million in cash has closed and all money received. Lexaria congratulates the new owners for having purchased a fine asset. >> FULL PR


FDA-Related News

We caught a couple of FDA news plays on this morning’s scan that we’ll want to keep an eye on:

ARCA BioPharma, Inc. ABIO has reported that the FDA “has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.” >> VIEW PR

Cytori Therapeutics, Inc. CYTX announced that the FDA granted approval “for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.” >> VIEW PR


Extended Watchlist:
 CYRN, SYMX, SNSS